医学
重性抑郁障碍
精神科
萧条(经济学)
认知行为疗法
自杀意念
随机对照试验
5-羟色胺再摄取抑制剂
观察研究
临床试验
毒物控制
药物滥用
临床心理学
自杀预防
氟西汀
再摄取抑制剂
心理健康
药物治疗
物质使用
自杀未遂
自杀行为
梅德林
伤害预防
纳入和排除标准
系统回顾
认知
数据提取
食品药品监督管理局
舍曲林
荟萃分析
药品
作者
Harlin Kaur,Aksha M Memon
出处
期刊:Cureus
[Cureus, Inc.]
日期:2025-12-30
卷期号:17 (12): e100438-e100438
标识
DOI:10.7759/cureus.100438
摘要
Major depressive disorder (MDD) in adolescents is a significant public health concern. When left untreated, it can lead to poor academic performance, substance use, and a heightened risk of suicide. The U.S. Food and Drug Administration (FDA) issued a black box warning on selective serotonin reuptake inhibitors (SSRIs) for patients under 18 due to concerns about increased suicidality - a decision that remains debated given SSRIs' role as first-line treatment for depression and the inherent suicide risk of untreated MDD. This systematized literature review examined the current evidence on the association between SSRI use and suicidality in adolescents with MDD following the FDA black box warning. Following a comprehensive PubMed search, studies were selected using predefined inclusion and exclusion criteria. Eight studies were selected for further data extraction and synthesis. Overall, observational studies found a small but measurable increase in suicidal risk with SSRI use, particularly during the early treatment phase, highlighting the need for close monitoring. Two randomized controlled trials (RCTs) reported increased treatment-emergent suicidality with SSRI monotherapy compared to cognitive behavioral therapy (CBT) or combination therapy, while two other RCTs found no significant association. Across studies, combination therapy with SSRIs and CBT tended to yield better outcomes and lower rates of suicidality. Current evidence reveals that SSRI treatment in childhood and adolescent MDD is associated with a small but measurable increase in suicidality, particularly in early treatment, underscoring the need for close clinical monitoring and concurrent psychotherapy. Clinicians are encouraged to monitor closely for suicidality during early treatment and to carefully weigh the benefits of SSRIs against the risks of untreated depression.
科研通智能强力驱动
Strongly Powered by AbleSci AI